• Je něco špatně v tomto záznamu ?

Inhibition of PIM Kinases in DLBCL Targets MYC Transcriptional Program and Augments the Efficacy of Anti-CD20 Antibodies

M. Szydłowski, F. Garbicz, E. Jabłońska, P. Górniak, D. Komar, B. Pyrzyńska, K. Bojarczuk, M. Prochorec-Sobieszek, A. Szumera-Ciećkiewicz, G. Rymkiewicz, M. Cybulska, M. Statkiewicz, M. Gajewska, M. Mikula, A. Gołas, J. Domagała, M. Winiarska, A....

. 2021 ; 81 (23) : 6029-6043. [pub] 20211008

Jazyk angličtina Země Spojené státy americké

Typ dokumentu časopisecké články, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc22011784

The family of PIM serine/threonine kinases includes three highly conserved oncogenes, PIM1, PIM2, and PIM3, which regulate multiple prosurvival pathways and cooperate with other oncogenes such as MYC. Recent genomic CRISPR-Cas9 screens further highlighted oncogenic functions of PIMs in diffuse large B-cell lymphoma (DLBCL) cells, justifying the development of small-molecule PIM inhibitors and therapeutic targeting of PIM kinases in lymphomas. However, detailed consequences of PIM inhibition in DLBCL remain undefined. Using chemical and genetic PIM blockade, we comprehensively characterized PIM kinase-associated prosurvival functions in DLBCL and the mechanisms of PIM inhibition-induced toxicity. Treatment of DLBCL cells with SEL24/MEN1703, a pan-PIM inhibitor in clinical development, decreased BAD phosphorylation and cap-dependent protein translation, reduced MCL1 expression, and induced apoptosis. PIM kinases were tightly coexpressed with MYC in diagnostic DLBCL biopsies, and PIM inhibition in cell lines and patient-derived primary lymphoma cells decreased MYC levels as well as expression of multiple MYC-dependent genes, including PLK1. Chemical and genetic PIM inhibition upregulated surface CD20 levels in an MYC-dependent fashion. Consistently, MEN1703 and other clinically available pan-PIM inhibitors synergized with the anti-CD20 monoclonal antibody rituximab in vitro, increasing complement-dependent cytotoxicity and antibody-mediated phagocytosis. Combined treatment with PIM inhibitor and rituximab suppressed tumor growth in lymphoma xenografts more efficiently than either drug alone. Taken together, these results show that targeting PIM in DLBCL exhibits pleiotropic effects that combine direct cytotoxicity with potentiated susceptibility to anti-CD20 antibodies, justifying further clinical development of such combinatorial strategies. SIGNIFICANCE: These findings demonstrate that inhibition of PIM induces DLBCL cell death via MYC-dependent and -independent mechanisms and enhances the therapeutic response to anti-CD20 antibodies by increasing CD20 expression.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc22011784
003      
CZ-PrNML
005      
20250120160054.0
007      
ta
008      
220425s2021 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1158/0008-5472.CAN-21-1023 $2 doi
035    __
$a (PubMed)34625423
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Szydłowski, Maciej $u Department of Experimental Hematology, Institute of Hematology and Transfusion Medicine, Warsaw, Poland $1 https://orcid.org/000000029419121X
245    10
$a Inhibition of PIM Kinases in DLBCL Targets MYC Transcriptional Program and Augments the Efficacy of Anti-CD20 Antibodies / $c M. Szydłowski, F. Garbicz, E. Jabłońska, P. Górniak, D. Komar, B. Pyrzyńska, K. Bojarczuk, M. Prochorec-Sobieszek, A. Szumera-Ciećkiewicz, G. Rymkiewicz, M. Cybulska, M. Statkiewicz, M. Gajewska, M. Mikula, A. Gołas, J. Domagała, M. Winiarska, A. Graczyk-Jarzynka, E. Białopiotrowicz, A. Polak, J. Barankiewicz, B. Puła, M. Pawlak, D. Nowis, J. Golab, AM. Tomirotti, K. Brzózka, M. Pacheco-Blanco, K. Kupcova, MR. Green, O. Havranek, B. Chapuy, P. Juszczyński
520    9_
$a The family of PIM serine/threonine kinases includes three highly conserved oncogenes, PIM1, PIM2, and PIM3, which regulate multiple prosurvival pathways and cooperate with other oncogenes such as MYC. Recent genomic CRISPR-Cas9 screens further highlighted oncogenic functions of PIMs in diffuse large B-cell lymphoma (DLBCL) cells, justifying the development of small-molecule PIM inhibitors and therapeutic targeting of PIM kinases in lymphomas. However, detailed consequences of PIM inhibition in DLBCL remain undefined. Using chemical and genetic PIM blockade, we comprehensively characterized PIM kinase-associated prosurvival functions in DLBCL and the mechanisms of PIM inhibition-induced toxicity. Treatment of DLBCL cells with SEL24/MEN1703, a pan-PIM inhibitor in clinical development, decreased BAD phosphorylation and cap-dependent protein translation, reduced MCL1 expression, and induced apoptosis. PIM kinases were tightly coexpressed with MYC in diagnostic DLBCL biopsies, and PIM inhibition in cell lines and patient-derived primary lymphoma cells decreased MYC levels as well as expression of multiple MYC-dependent genes, including PLK1. Chemical and genetic PIM inhibition upregulated surface CD20 levels in an MYC-dependent fashion. Consistently, MEN1703 and other clinically available pan-PIM inhibitors synergized with the anti-CD20 monoclonal antibody rituximab in vitro, increasing complement-dependent cytotoxicity and antibody-mediated phagocytosis. Combined treatment with PIM inhibitor and rituximab suppressed tumor growth in lymphoma xenografts more efficiently than either drug alone. Taken together, these results show that targeting PIM in DLBCL exhibits pleiotropic effects that combine direct cytotoxicity with potentiated susceptibility to anti-CD20 antibodies, justifying further clinical development of such combinatorial strategies. SIGNIFICANCE: These findings demonstrate that inhibition of PIM induces DLBCL cell death via MYC-dependent and -independent mechanisms and enhances the therapeutic response to anti-CD20 antibodies by increasing CD20 expression.
650    _2
$a zvířata $7 D000818
650    _2
$a antigeny CD20 $7 D018951
650    _2
$a protinádorové látky imunologicky aktivní $x farmakologie $7 D000074322
650    _2
$a apoptóza $7 D017209
650    _2
$a proliferace buněk $7 D049109
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a regulace genové exprese u nádorů $x účinky léků $7 D015972
650    _2
$a lidé $7 D006801
650    _2
$a difúzní velkobuněčný B-lymfom $x farmakoterapie $x genetika $x metabolismus $x patologie $7 D016403
650    _2
$a myši $7 D051379
650    _2
$a myši SCID $7 D016513
650    _2
$a fosforylace $7 D010766
650    _2
$a inhibitory proteinkinas $x farmakologie $7 D047428
650    _2
$a protoonkogenní proteiny c-myc $x genetika $x metabolismus $7 D016271
650    _2
$a protoonkogenní proteiny c-pim-1 $x antagonisté a inhibitory $7 D051573
650    _2
$a rituximab $x farmakologie $7 D000069283
650    _2
$a nádorové buňky kultivované $7 D014407
650    _2
$a xenogenní modely - testy protinádorové aktivity $7 D023041
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Garbicz, Filip $u Department of Experimental Hematology, Institute of Hematology and Transfusion Medicine, Warsaw, Poland $u Postgraduate School of Molecular Medicine, Medical University of Warsaw, Poland $1 https://orcid.org/0000000255481564
700    1_
$a Jabłońska, Ewa $u Department of Experimental Hematology, Institute of Hematology and Transfusion Medicine, Warsaw, Poland
700    1_
$a Górniak, Patryk $u Department of Experimental Hematology, Institute of Hematology and Transfusion Medicine, Warsaw, Poland
700    1_
$a Komar, Dorota $u Department of Experimental Hematology, Institute of Hematology and Transfusion Medicine, Warsaw, Poland
700    1_
$a Pyrzyńska, Beata $u Department of Immunology, Medical University of Warsaw, Warsaw, Poland
700    1_
$a Bojarczuk, Kamil $u Department of Experimental Hematology, Institute of Hematology and Transfusion Medicine, Warsaw, Poland $u Department of Hematology and Medical Oncology, University Medicine Göttingen, Göttingen, Germany $1 https://orcid.org/0000000261104060
700    1_
$a Prochorec-Sobieszek, Monika $u Department of Diagnostic Hematology, Institute of Hematology and Transfusion Medicine, Warsaw, Poland
700    1_
$a Szumera-Ciećkiewicz, Anna $u Department of Diagnostic Hematology, Institute of Hematology and Transfusion Medicine, Warsaw, Poland $1 https://orcid.org/0000000150283422
700    1_
$a Rymkiewicz, Grzegorz $u Flow Cytometry Laboratory, Department of Pathology and Laboratory Diagnostics, Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland $1 https://orcid.org/0000000234788014
700    1_
$a Cybulska, Magdalena $u Department of Genetics, Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland
700    1_
$a Statkiewicz, Małgorzata $u Department of Genetics, Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland
700    1_
$a Gajewska, Marta $u Department of Genetics, Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland
700    1_
$a Mikula, Michał $u Department of Genetics, Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland
700    1_
$a Gołas, Aniela $u Ryvu Therapeutics, Cracow, Poland
700    1_
$a Domagała, Joanna $u Postgraduate School of Molecular Medicine, Medical University of Warsaw, Poland $u Department of Immunology, Medical University of Warsaw, Warsaw, Poland
700    1_
$a Winiarska, Magdalena $u Department of Immunology, Medical University of Warsaw, Warsaw, Poland
700    1_
$a Graczyk-Jarzynka, Agnieszka $u Department of Immunology, Medical University of Warsaw, Warsaw, Poland $1 https://orcid.org/0000000179800542
700    1_
$a Białopiotrowicz, Emilia $u Department of Experimental Hematology, Institute of Hematology and Transfusion Medicine, Warsaw, Poland
700    1_
$a Polak, Anna $u Department of Experimental Hematology, Institute of Hematology and Transfusion Medicine, Warsaw, Poland
700    1_
$a Barankiewicz, Joanna $u Department of Hematology, Institute of Hematology and Transfusion Medicine, Warsaw, Poland
700    1_
$a Puła, Bartosz $u Department of Hematology, Institute of Hematology and Transfusion Medicine, Warsaw, Poland
700    1_
$a Pawlak, Michał $u Department of Experimental Hematology, Institute of Hematology and Transfusion Medicine, Warsaw, Poland
700    1_
$a Nowis, Dominika $u Laboratory of Experimental Medicine, Medical University of Warsaw, Warsaw, Poland $1 https://orcid.org/0000000327489523
700    1_
$a Golab, Jakub $u Department of Immunology, Medical University of Warsaw, Warsaw, Poland
700    1_
$a Tomirotti, Andrea M $u Department of Experimental and Translational Oncology, Menarini Ricerche, Pomezia, Italy
700    1_
$a Brzózka, Krzysztof $u Ryvu Therapeutics, Cracow, Poland
700    1_
$a Pacheco-Blanco, Mariana $u BIOCEV, First Faculty of Medicine, Charles University, Prague, Czech Republic
700    1_
$a Kupcová, Kristýna $u BIOCEV, First Faculty of Medicine, Charles University, Prague, Czech Republic $7 xx0328095
700    1_
$a Green, Michael R $u Department of Lymphoma and Myeloma, University of Texas MD Anderson Cancer Center, Houston, Texas $u Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas
700    1_
$a Havranek, Ondrej $u BIOCEV, First Faculty of Medicine, Charles University, Prague, Czech Republic $u Department of Hematology, First Faculty of Medicine, Charles University and General University Hospital, Prague, Czech Republic
700    1_
$a Chapuy, Bjoern $u Department of Hematology and Medical Oncology, University Medicine Göttingen, Göttingen, Germany $1 https://orcid.org/0000000264858773
700    1_
$a Juszczyński, Przemysław $u Department of Experimental Hematology, Institute of Hematology and Transfusion Medicine, Warsaw, Poland. pjuszczynski@ihit.waw.pl
773    0_
$w MED00009437 $t Cancer research $x 1538-7445 $g Roč. 81, č. 23 (2021), s. 6029-6043
856    41
$u https://pubmed.ncbi.nlm.nih.gov/34625423 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20220425 $b ABA008
991    __
$a 20250120160051 $b ABA008
999    __
$a ok $b bmc $g 1789403 $s 1162982
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2021 $b 81 $c 23 $d 6029-6043 $e 20211008 $i 1538-7445 $m Cancer research $n Cancer Res $x MED00009437
LZP    __
$a Pubmed-20220425

Najít záznam

Citační ukazatele

Možnosti archivace